Biologics in the Treatment of Severe Uncontrolled Asthma in Children

Nightingale Syabbalo
Professor of Physiology and Medicine, Nabanji Medical Centre, Lusaka, ZAMBIA.

Corresponding Author: Nightingale Syabbalo, Professor of Physiology and Medicine, Nabanji Medical Centre, Lusaka, ZAMBIA.

Received Date: June 4, 2021; Accepted Date: June 17, 2021; Published Date: June 30, 2021

Citation: Nightingale Syabbalo (2021). Biologics in the Treatment of Severe Uncontrolled Asthma in Children. J Thoracic Disease and Cardiothoracic Surgery, 2(2); DOI: 10.31579/2693-2156/024

Copyright: © 2021, Nightingale Syabbalo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Asthma is the most common chronic disease in children, currently affecting about 7 million children. Severe uncontrolled asthma is rare in children with a prevalence of about 2.1% to 5%, yet inflicts a disproportionate health burden. Children with severe asthma have increased risk of life-threatening exacerbations, frequent hospitalization, worsening health-related quality of life, and impaired physical activity. Severe asthma in childhood is associated with long-term morbidities, such as bronchiolitis obliterans, impaired airway development, and development of chronic obstructive pulmonary disease in adulthood. Childhood asthma like adult-onset asthma, is classified into four cellular inflammatory phenotypes using induced sputum cytometry. The four phenotypes of asthma include eosinophilic asthma, neutrophilic asthma, paucigranulocytic asthma, and mixed cellularity asthma. The pathophysiological mechanisms of asthma involve airway inflammation and remodeling. Inflammatory mediators such as cytokines, chemokines, adhesion molecules, and growth factors play a key role in orchestration airway remodeling. During airway inflammation, cytokines secreted by type 2 helper (Th2) lymphocytes, such as interleukin-5 (IL-5), IL-4, IL-13, IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) play a key role in the pathogenesis of eosinophilic asthma. Whereas, the Th17 axis cytokines, including IL-17, IL-23, and IL-8 are responsible for the pathophysiology of neutrophilic asthma. The airway structural changes due to airway remodeling lead to thickening of the airway wall, narrowing of the bronchial lumen, airway obstruction, and decline in pulmonary function. Most of the children with asthma respond to low and medium inhaled corticosteroids, however a significant proportion still have severe asthma uncontrolled on the standard of care. The most common asthma phenotype in children is eosinophilic asthma, which responds superbly to biologic therapy. Children with severe asthma require add-on targeted interleukin antagonists (ILA), such as mepolizumab (anti-IL-5), benralizumab (anti-IL-5Rα), and dupilumab (anti-4Rα). ILAs have been shown to ameliorate asthma symptoms, reduce moderate and severe exacerbations, and improve pulmonary function. Additionally, ILAs have been demonstrated to improve the health-related quality of life, and have steroid sparing effect.

Key words: airway remodeling; biologics; childhood asthma; interleukins; eosinophilic asthma; severe exacerbations; pathophysiology; obesity

Introduction

Asthma is a significant public health problem, affecting more than 358 million people globally [1], and is the most common chronic disease among children [3,4], affecting about 7 million children [4]. Asthma is a heterogeneous chronic airway disease with several distinct phenotypes characterized by different immunopathological pathways, clinical presentation, physiology, co-morbidities, biomarker of allergic inflammation, and response to treatment [5-10]. There are four cellular inflammatory phenotypes of asthma classified using induced sputum cytometry. The four phenotypes of asthma include eosinophilic asthma, neutrophilic asthma, paucigranulocytic asthma, and mixed cellularity asthma [7,11]. Patients with eosinophilic asthma have an eosinophil count ≥3% [12-14], whereas patients with neutrophilic asthma have elevated sputum neutrophil count between ≥61% [14] and ≥64% [15], depending on the study. Mixed cellularity phenotype is typified by increase in both eosinophils (>3%), and neutrophils (>61% or >64%) [15]. Paucigranulocytic phenotype includes patients with very few eosinophils (<3%), and neutrophils (<61% or <64%) in induced sputum [15]. Non-eosinophilic asthma designates patients with low sputum and/or blood eosinophil counts (<3%), and include neutrophilic asthma, and paucigranulocytic phenotype [16]. Approximately 40-60% of patients with severe asthma have eosinophilic phenotype [17-21], whereas, the remaining patients have the non-eosinophilic phenotype. Eosinophilic asthma is the most common...
phenotype in children presenting with severe acute asthma; representing about 50% of the patients [22,23]. Paucigranulocytic asthma is most common in children and adults with stable asthma [23], however, acute severe neutrophilic asthma is most common in adult patients [22,23].

The pathophysiological mechanisms of asthma involve airway inflammation and remodeling. Inflammatory mediators such as cytokines, chemokines, adhesion molecules, enzymes, and growth factors play a key role in propagating airway remodeling. During airway inflammation, cytokines secreted by type 2 helper (Th2) lymphocytes, play a key role in the pathogenesis of Th2-high eosinophilic asthma. On the other hand, the Th17 axis cytokines are responsible for the pathophysiology of Th2-low neutrophilic asthma [24].

Most children with asthma respond to low and moderate doses of inhaled corticosteroids (ICS). However, about 5% of children have severe uncontrolled asthma despite maximal standard of care, including high dose ICS, which are associated with serious side effects. Children with severe uncontrolled asthma require add-on biological treatment, such as omalizumab (anti-IgE), mepolizumab (anti-IL-5), benralizumab (anti-IL-5Ra), and dupilumab (anti-4Ra). ILAs have been shown to ameliorate asthma symptoms, reduce moderate and severe exacerbations, and improve pulmonary function. Additionally, ILAs have been demonstrated to improve health-related quality of life, and have steroid-sparing effects [25]. This review highlights targeted treatment of severe uncontrolled asthma using the currently approved biologics for the treatment of childhood asthma.

Pathophysiology of Asthma

The pathophysiology and immunological mechanisms in the pathogenesis of childhood asthma and adult-onset asthma are basically similar. Airway inflammation and remodeling plays a key role in the pathogenesis of childhood asthma. During airway inflammation, cytokines secreted by type 2 helper (Th2) lymphocytes (CD4+), and innate lymphoid cells

<table>
<thead>
<tr>
<th>Epithelial cell metaplasia and desquamation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secretion of cytokines, chemokines, adhesion molecules, and growth factors</td>
</tr>
<tr>
<td>Submucosal glands and goblet cell hyperplasia, and mucus hypersecretion</td>
</tr>
<tr>
<td>Epithelial mesenchymal transition</td>
</tr>
<tr>
<td>Activation of fibroblasts, and myofibroblasts</td>
</tr>
<tr>
<td>Deposition of extracellular matrix proteins</td>
</tr>
<tr>
<td>Reticular basement membrane thickening</td>
</tr>
<tr>
<td>Subepithelial fibrosis</td>
</tr>
<tr>
<td>Airway smooth muscle hyperplasia, and hypertrophy</td>
</tr>
<tr>
<td>Angiogenesis, vascular expansion, and vasodilatation</td>
</tr>
</tbody>
</table>

Table 1. Pathophysiologic mechanisms of airway remodeling in severe childhood asthma

Childhood Asthma

Asthma is the most common chronic disease in childhood, affecting about 10-15% of school-age children [61]. It is most common in boys [1,62]. Severe uncontrolled asthma in children only accounts for 2 to 5% of childhood asthma [63-65], but contributes to huge costs, and utilization of health care resources [66,67]. Severe asthma is associated with significant morbidity, such as increased risk of life threatening exacerbations, frequent hospitalization, worsening health-related quality of life, and impaired physical activity [68-70]. Severe asthma in children may impair airway development and reduce maximally attained lung function, and the lung function loss may persist in adult life [62]. It is also associated with long-term morbidities, such as bronchiolitis obliterans [71]; progressive airflow limitation [70]; and development of chronic obstructive pulmonary disease in adulthood [72-75]. Furthermore, children with asthma are more susceptible to medication-related side effects, particularly with the new biologics [75].

Asthma in children is associated with co-morbidities [76,77], such as allergic rhinitis [78,79], chronic rhinosinusitis and nasal polyps [80,81], atopic dermatitis [82,83], gastroesophageal reflux disease [84,85], obstructive sleep apnea [86,87], food allergy [88], and obesity [89,90]. Obesity is associated with decreased response to inhaled corticosteroids in overweight and obese asthmatic children [91]. Co-morbid diseases associated with asthma may make asthma control difficult, they require medical and/or surgical treatment [36].

Children with severe asthma have elevated biomarkers of Th2 eosinophilic inflammation, such as high sputum and blood eosinophil counts, high IgE levels [92-94], high fractional exhaled nitric oxide

Auctores Publishing – Volume 2(2)-024 www.auctoresonline.org
ISSN: 2693-2156
Page 2 of 8
(FeNO) [95,96], and elevated serum periostin concentration [92]. Biomarkers of eosinophilic inflammation should be assessed for selection of asthmatic children for add-on treatment with biologics [96,97]. Children with persistent symptoms, and exacerbations despite correct inhaler technique and adherence should be referred to an asthma specialist with expertise in severe asthma [70].

### Treatment of Severe Asthma in Children

Childhood asthma is usually controlled with low to moderate doses of inhaled corticosteroids. However, about 5% of children experience severe uncontrolled asthma despite maximal standard of care, including high dose ICS (GINA steps 4 and 5) [1]. High dose ICS have serious side effects in children including impaired growth velocity, decrease bone mineral density, and pneumonia. Children with severe uncontrolled asthma may require targeted add-on biologic treatment, which has been available for adults since the approval of omalizumab (Xolair®) on June 30, 2003. Although most of the clinical trials on biologics have been conducted in adult patients with asthma [98], biologics are very effective and safe as add-on treatment for severe eosinophilic asthma in children. Currently, there are four biologics which have been approved for add-on treatment of severe childhood asthma [99]. They include omalizumab (anti-IgE) [100,101], mepolizumab (anti-IL-5) [102,103], benralizumab (anti-IL-5Rα) [104,105], and dupilumab (anti-4Rα) [106,107]. Table 2 shows the list of the current approved biologics for the treatment of childhood asthma, and some ILAs still in development, or phased out of the clinical trials.

<table>
<thead>
<tr>
<th>Biologic</th>
<th>Target</th>
<th>Stage of Development</th>
<th>Childhood asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omalizumab</td>
<td>IgE</td>
<td>Marketed 2003</td>
<td>Approved</td>
</tr>
<tr>
<td>Mepolizumab</td>
<td>IL-5</td>
<td>Marketed 2015</td>
<td>Approved</td>
</tr>
<tr>
<td>Reslizumab</td>
<td>IL-5</td>
<td>Marketed 2016</td>
<td>Phase III</td>
</tr>
<tr>
<td>Benralizumab</td>
<td>IL-5R</td>
<td>Marketed 2017</td>
<td>Approved</td>
</tr>
<tr>
<td>Dupilumab</td>
<td>IL-4α/IL-13</td>
<td>Marketed 2018</td>
<td>Approved</td>
</tr>
<tr>
<td>Tezepelumab</td>
<td>TSLP</td>
<td>Marketed 2018</td>
<td>Not approved</td>
</tr>
<tr>
<td>Pitrakinra</td>
<td>IL-4α/IL-13</td>
<td>II</td>
<td>NA</td>
</tr>
<tr>
<td>Lebrikizumab</td>
<td>IL-13</td>
<td>III</td>
<td>NA</td>
</tr>
<tr>
<td>Tralokinumab</td>
<td>IL-13</td>
<td>III</td>
<td>NA</td>
</tr>
<tr>
<td>Fezakinumab</td>
<td>IL-22</td>
<td>II</td>
<td>NA</td>
</tr>
<tr>
<td>Brodalumab</td>
<td>IL-17RA</td>
<td>II</td>
<td>NA</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>IL-17A</td>
<td>II</td>
<td>NA</td>
</tr>
<tr>
<td>Risankizumab</td>
<td>IL-23</td>
<td>II</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Abbreviations:** FDA, Food and Drug Administration; IL, interleukin; R, receptor; TSLP, thymic stromal lymphopoietin; NA, not approved for adults and children. Brodalumab, secukinumab, and risankizumab are approved for the treatment of plaque psoriasis.

### Table 2. Biologics for the treatment of asthma, their targets, and date of approval by FDA

Add-on biologics have been shown to reduce asthma symptoms, decrease moderate to severe exacerbations, and improve pulmonary function in children with severe asthma [108-114]. Additionally, biologics improve health-related quality of life, and have been used to taper or stop oral corticosteroids in patients with severe asthma [102,104,115]. The dosages of the currently approved biologics by the US Food and Drug Administration (FDA) are shown in Table 3.

<table>
<thead>
<tr>
<th>Biologic</th>
<th>Dosage</th>
<th>Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omalizumab</td>
<td>75-375 mg SC Q 2/4 wk</td>
<td>Reduces exacerbations (47-53%)</td>
</tr>
<tr>
<td>Mepolizumab</td>
<td>100 mg SC Q 4 wk</td>
<td>Reduces exacerbations (50-60%)</td>
</tr>
<tr>
<td>Benralizumab</td>
<td>30 mg SC Q 8 wk</td>
<td>Reduces exacerbations (25-60%)</td>
</tr>
<tr>
<td>Dupilumab</td>
<td>300 mg SC Q 2 wk</td>
<td>Reduces exacerbations (60-80%)</td>
</tr>
<tr>
<td>Tezepelumab</td>
<td>210 mg SC Q 4 wk</td>
<td>Reduces exacerbations (41-56%)</td>
</tr>
</tbody>
</table>

**Abbreviations:** IV, intravenous; SC, subcutaneous, Q, every; wk, weeks. Note: pediatric dosages depend on body weight of child or adolescent.

### Table 3. Dosages of approved biologics by the Food and Drug Administration for the treatment of severe asthma

Children and adolescent dosages vary with age and weight of the patient, and also vary with authors.

Biologics are safe for add-on treatment of severe asthma in children. They have almost similar manageable side effects because of their immunological effects on eosinophils, and other systemic effects, such as injection site reaction, respiratory tract infection, nasopharyngitis, sinusitis, conjunctivitis, headache, arthralgia, myalgia, muscle weakness, parasitosis, and rarely anaphylaxis (Table 4) [36].
Eosinophils play an important role in protection against parasitic infection, including helminth infestation. Patients with pre-existing helminth infections should be treated for the infection before initiating biologic therapy. If individuals become infected whilst receiving treatment with biologics and do not respond to anti-helminth treatment, temporary discontinuation of the biologic should be considered [36].

Notably, some of the biologics, such as omalizumab, and dupilumab also ameliorate, and are approved for the treatment other co-morbid conditions associated with childhood asthma, such as allergic rhinitis, chronic rhinosinusitis with nasal polyps, and atopic dermatitis [116-119]. Dupilumab (Dupixent®) has been nicknamed “magic bullet” because it is the only biologic which has been approved by the FDA for the treatment of eosinophilic asthma [117,118]; chronic rhinosinusitis with nasal polyps [117,119]; atopic dermatitis [117,120]; and eosinophilic esophagitis [118,121,122]. The different immunopathological pathways of dupilumab in the treatment of asthma, allergic rhinitis, atopic dermatitis, and chronic rhinosinusitis are explained in detail elsewhere [123]. Dupixent® has been shown to be very effective and safe in the treatment of these conditions, and to improve the quality of life in children and adults [124]. The latest approved biologic for the treatment of severe refractory asthma is tezepelumab [125,126]. Tezepelumab is a fully human monoclonal Ig2λ antibody that specifically ligates TSLP by binding to its receptor TSLPR, thereby blocking human TSLP-TSLPR interaction [127]. Menziew-Gow et al. [128] have shown that tezepelumab significantly reduces the annualized asthma exacerbation in adolescent and adult asthmatics by 56% in patients with eosinophil count ≥ 300 cells/µl, and by 41% in patients with eosinophil count < 300 cells/µl [128]. Tezepelumab also resulted in significant improvement in lung function, and health-related quality of life [128]. This study demonstrates the efficacy of blocking the epithelial cell-derived (alarmin) cytokines, such as TSLP in the treatment of severe, uncontrolled asthma [125,128,129]. Although this study was also conducted on adolescents (12-17 years), tezepelumab is currently only approved by the US FDA for the treatment of severe asthma irrespective of the eosinophil count in adults [129].

Severe, uncontrolled childhood asthma may also be treated with Complementary and Integrative Medicine (CIM), including Traditional Chinese Medicine (TCM). In order to treat severe asthma, one must understand the function of the body as a whole, in its energy level [131].

<table>
<thead>
<tr>
<th>Side effect</th>
<th>Headache</th>
<th>Myalgia</th>
<th>Arthralgia</th>
<th>Muscle weakness</th>
<th>Fatigue</th>
<th>Helminth infestation</th>
<th>Rarely anaphylaxis</th>
</tr>
</thead>
</table>

**Table 4. Side-effects of biological treatment in patients with eosinophilic asthma**

Asthma is the most common chronic disease in childhood, affecting about 10-15% of school-age children. Severe uncontrolled asthma in children is not common, but contributes to huge costs, and utilization of health care resources. It is associated with significant morbidity, such as increased risk of life threatening exacerbations, frequent hospitalization, and worsening health-related quality of life. Cytokines secreted by Th2 lymphocytes, and Th17 cells, such as IL-5, IL-4, IL-13, IL-25, IL-33, and TSLP; and IL-17, respectively play an important role in the pathogenesis of asthma. Most children with asthma are controlled on low to moderate dose of ICS. However, a significant proportion of children have severe asthma uncontrolled on high dose ICS. Children with severe persistent asthma require add-on treatment with biologics targeting the instigating interleukins. Interleukin antagonists have been shown to reduce asthma symptoms, decrease moderate to severe exacerbations, and improve pulmonary function in children with severe asthma. Additionally, they improve health-related quality of life, and have corticosteroids-sparing effects. Dupilumab is also effective in the treatment of childhood asthma-associated disorders, such as chronic rhinosinusitis with nasal polyps, eczema, and eosinophilic esophagitis.

**References**


asthma. The phase 3 VOYAGE study. Am J Respir Crit Care Med; 203; A1204.
122. FDA grants Dupixent (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis. Accesses September 14, 2020.

**Ready to submit your research? Choose Auctores and benefit from:**

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.